Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Outcomes Database to prospectivelY aSSEss the changing TherapY landscape in Renal Cell Carcinoma ODYSSEY RCC
Study Type: Treatment
Phase: IV
NCTID: NCT04919122
Principal Investigator:
Elizabeth Wulff-Burchfield
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis RadiCal
Study Type: Treatment
Phase: II
NCTID: NCT04071223
Principal Investigator:
Elizabeth Wulff-Burchfield
Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients with Renal Cell Carcinoma
An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma ccRCC in patients with renal masses utilizing Zirconium-labelled girentuximab 89Zr-DFO-girentuximab
A Phase II Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Renal Tumors Classification Biology and Banking Study: Study of Kidney Tumors in Younger Patients
Study Type: Other
Phase: N/A
NCTID: NCT00898365
Principal Investigator:
Keith August
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma tRCC
Study Type: Treatment
Phase: II
NCTID: NCT03595124
Principal Investigator:
Keith August
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors DAWT and Relapsed Favorable Histology Wilms Tumors FHWT
Study Type: Treatment
Phase: II
NCTID: NCT04322318
Principal Investigator:
Keith August
A Phase III RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy PROSPER RCC
Study Type: Treatment
Phase: III
NCTID: NCT03055013
Principal Investigator:
Elizabeth Wulff-Burchfield
PD-Inhibitor Nivolumab and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Study Type: Treatment
Phase: III
NCTID: NCT03793166
Principal Investigator:
Elizabeth Wulff-Burchfield